Medifill is an Irish formulator and producer of medical-grade cyanoacrylate adhesives with a clean room and manufacturing capabilities. Medifill produces advanced technology that is tailored for the wound closure market. The formulations are said to enable fast, safe, and effective wound closure.
GEM is an Italian manufacturer and provider of medical adhesives and application devices approved and certified for over 80 internal indications. The acquisition establishes a European headquarters for HB Fuller’s medical adhesive technologies business and expands the company’s medical adhesive offerings.
“Tissue adhesives designed for internal use offer innovative alternatives to traditional sutures, staples and embolizing agents,” says HB Fuller president and CEO Celeste Mastin. “With the purchase of GEM, Medifill, and our previous acquisitions in this space, H.B. Fuller has now built a Medical Adhesive Technologies business founded on our expertise in cyanoacrylate chemistry, and we have extended our penetration into a global footprint.”
Subject to customary closing conditions and regulatory approvals, the GEM acquisition is expected to close in February 2025.
Last month, HB Fuller appointed Teresa (Terry) J. Rasmussen chair of its board of directors following the retirement of Lee R. Mitau, effective 22 January 2025.
“We are pleased to appoint a leader of Terry’s calibre as the new chair of HB Fuller’s board of directors,” said Celeste Mastin, HB Fuller’s president and chief executive officer. “Having worked closely with Terry, I know firsthand that she is a visionary leader who brings global perspective and deep customer and go-to-market expertise to the role. We look forward to continuing to benefit from Terry’s extensive background in the financial services industry as we expand our presence in new high-growth end markets and transform our portfolio to become a 20% EBITDA margin business.”
